Rohto Pharmaceutical Co., Ltd. 4527

Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals, with a primary focus on eye care.

Rohto PharmaceuticalLtd (TSE:4527) is back in focus after the board approved a higher year end dividend from retained earnings and reaffirmed its dividend approach alongside fresh earnings guidance and responses to shareholder proposals. See our latest analysis for Rohto PharmaceuticalLtd. The recent dividend increase, fresh earnings guidance and board responses to activist proposals have coincided with a 1 month share price return of 8.76% and a 1 year total shareholder return of 26.75%. At...